Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H in Adult T-Cell Leukemia
NCT00061048Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Jul 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in adult T-cell leukemia-lymphoma (ATLL), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate at 60 months, Overall Survival at 60 months and 1 more. Started May 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00061048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061048.